RT Journal Article SR Electronic T1 L-[3-18F]-α-Methyltyrosine Accumulation as a Definitive Chemoradiotherapy Response Predictor in Patients with Esophageal Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 909 OP 913 VO 34 IS 2 A1 MAKOTO SOHDA A1 HIROAKI HONJYO A1 KEIGO HARA A1 DAIGO OZAWA A1 SHIGEMASA SUZUKI A1 NARITAKA TANAKA A1 AKIHIKO SANO A1 MAKOTO SAKAI A1 TAKEHIKO YOKOBORI A1 TAKANORI INOSE A1 TATSUYA MIYAZAKI A1 HITOSHI OJIMA A1 TETSUYA HIGUCHI A1 YOSHITO TSUSHIMA A1 HIROYUKI KUWANO YR 2014 UL http://ar.iiarjournals.org/content/34/2/909.abstract AB Aims: L-[3-18F]-α-Methyltyrosine (18F-FAMT) has high specificity for malignant tumors on positron emission tomography (PET), and its role and potential usefulness has been previously investigated in operable esophageal carcinoma. We aimed to assess the ability of 18F-FAMT PET to predict the response of esophageal cancer to definitive chemoradiotherapy. Patients and Methods: We retrospectively reviewed 40 patients with esophageal cancer imaged with 18F-FAMT PET. The relationship between 18F-FAMT PET uptake before chemoradiotherapy and clinical outcomes was assessed. Results: The primary tumor was visualized in 95% patients. 18F-FAMT uptake was significantly positively correlated with lymph node metastasis. The low-18F-FAMT accumulation group had significantly higher complete response (CR) rates than did the high-accumulation group. The addition of a lymph node metastasis category with low 18F-FAMT uptake provides a more precise predictor of CR. Conclusion: 18F-FAMT uptake prior to treatment is a good predictor of CR rate after CRT for esophageal cancer.